Aflibercept Ophthalmic

Introduction Overview

Generic Name

aflibercept ophthalmic

Brand Name

Eylea

Dosage Form

single-dose pre-filled syringe for ophthalmic injection (2 mg), single-dose vial for ophthalmic injection (2 mg)

Drug Class

Anti-angiogenic ophthalmic agents

Pharmacokinetics

Absorption:
Eylea (aflibercept ophthalmic) is administered via intravitreal injection directly into the vitreous humor of the eye, thereby bypassing gastrointestinal absorption and systemic administration. Consequently, systemic absorption is minimal. After intravitreal injection, aflibercept exhibits local ocular presence with an intended local effect on retinal tissues. Systemic exposure following intravitreal administration is low, due to the blood-ocular barrier, but measurable systemic concentrations may occur and have been detected in plasma at low levels. The slow clearance from the vitreous humor ensures a sustained presence at the site of action, supporting intermittent dosing schedules.

Distribution:
Upon intravitreal injection, aflibercept distributes within the vitreous cavity and penetrates the retina where it binds vascular endothelial growth factor (VEGF). The volume of distribution is limited to the local ocular tissues due to the route of administration. Aflibercept is a recombinant fusion protein with large molecular size, limiting its diffusion into systemic circulation. Small systemic concentrations detected post-injection reflect distribution into plasma from ocular compartments, but systemic exposure is minimal. The intraocular half-life in humans is estimated to be approximately 7 days, supporting repetitive dosing intervals.

Metabolism:
Aflibercept is a recombinant fusion protein comprising portions of VEGF receptors fused to IgG1 Fc regions. It undergoes proteolytic degradation via enzymatic catabolism similar to endogenous proteins. This metabolic breakdown occurs primarily within ocular tissues locally, and systemically if absorbed. Unlike small molecule drugs, aflibercept is metabolized through general protein catabolic pathways rather than hepatic enzyme-mediated metabolism. The metabolism results in smaller peptide fragments and amino acids recycled by the body.

Elimination:
Aflibercept is eliminated primarily through proteolytic catabolism within ocular tissues and systemic circulation. The vitreous elimination half-life is approximately 7 days, with a duration of action that allows dosing intervals between 4 to 12 weeks depending on indication. Minor systemic elimination occurs through reticuloendothelial metabolism and renal clearance of peptides. Due to its large size and local administration, renal elimination is negligible for the intact protein. The slow ocular elimination supports prolonged therapeutic effects on pathogenic retinal neovascularization.

Dosage Forms

Available Dosage Forms:
Eylea is available exclusively for intravitreal injection in ophthalmic preparations designed for single use. The formulations include:
- Single-dose pre-filled syringe containing 2 mg aflibercept in 0.05 mL (40 mg/mL solution)
- Single-dose glass vial containing 2 mg aflibercept in 0.05 mL (40 mg/mL solution)
Neither formulation contains antimicrobial preservatives to ensure sterility and reduce contamination risk during ocular injection.

Dosages for Adults and Adolescents:
The recommended dose of Eylea is 2 mg (0.05 mL) administered by intravitreal injection into each affected eye. Dosing regimens vary by indication as follows:
- Neovascular (wet) age-related macular degeneration (nAMD): Initial dosing of 2 mg every 4 weeks for first 3 months, followed by maintenance dosing every 8 weeks. Some patients may require monthly dosing indefinitely. After 1 year, some patients may lengthen interval to 12 weeks, though with potential diminished efficacy.
- Macular edema following retinal vein occlusion (RVO): 2 mg every 4 weeks (approximately every 25 days), with no standard maintenance interval established.
- Diabetic macular edema (DME) and diabetic retinopathy (DR): Initial 5 injections of 2 mg every 4 weeks, then maintenance injections every 8 weeks. Some patients may necessitate monthly injections.

Specific Patient Populations:
- Retinopathy of prematurity (ROP): Dosing differs significantly; a single intravitreal injection of 0.4 mg (0.01 mL) is administered, which may be repeated with a minimum interval of 10 days between doses in the same eye. Treatment may be given to both eyes on the same day if clinically indicated.
- Pediatric use beyond ROP is not extensively established.
- No dosage adjustments are generally required for renal or hepatic impairment due to local administration.
- Pregnant women should avoid treatment due to potential fetal risk, and breastfeeding is contraindicated during treatment.

Comprehensive dosing schedules must be individualized based on therapeutic response and ocular examination findings, under specialized ophthalmologic supervision.

Mechanism Of Action

Eylea (aflibercept ophthalmic) functions as a potent inhibitor of pathological angiogenesis primarily through its interaction with vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), critical mediators of abnormal blood vessel formation and vascular permeability in ocular diseases. Molecularly, aflibercept is a recombinant fusion protein combining the extracellular binding domains of human VEGF receptors 1 and 2 fused to the Fc portion of human IgG1. This unique design creates a decoy receptor with high affinity for VEGF-A, VEGF-B, and PlGF isoforms, effectively neutralizing their biological activity.

At the cellular level, aflibercept sequesters VEGF in the vitreous humor, preventing it from binding to endogenous VEGF receptors on vascular endothelial cells. This blockade disrupts VEGF-induced signaling pathways responsible for endothelial cell proliferation, migration, and new vessel formation (angiogenesis), as well as vascular permeability leading to retinal edema. Aflibercept's ability to bind PlGF additionally subdues inflammatory and angiogenic responses, which distinguishes it from other VEGF inhibitors targeting only VEGF-A.

Biochemically, inhibition of VEGF and PlGF results in reduced activation of receptor tyrosine kinases, thereby downregulating downstream signaling cascades such as the PI3K-Akt and MAPK pathways. This curtails pathological neovascularization and decreases leakage from abnormal vessels, crucial for managing retinal disorders characterized by fluid accumulation and hemorrhage.

Clinically, these mechanistic effects translate into stabilization or improvement of vision in patients affected by neovascular (wet) age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion-induced macular edema. Comparatively, Eylea exhibits a broader VEGF isoform binding profile and higher affinity than other anti-VEGF agents such as ranibizumab and bevacizumab, which may contribute to its efficacy and dosing intervals. Extensive clinical trials have validated its capacity to reduce vision loss and improve retinal anatomy with a generally favorable safety profile.

Pharmacological Actions

Inhibition of vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) binding, preventing pathological angiogenesis.
Reduction of neovascularization and abnormal blood vessel growth in retinal tissues.
Decrease in vascular permeability leading to reduced macular edema and fluid accumulation.
Suppression of inflammatory processes associated with retinal vascular diseases.
Improvement and stabilization of visual acuity in patients with wet age-related macular degeneration.
Mitigation of progression of diabetic retinopathy and diabetic macular edema.
Reduction of retinal swelling following retinal vein occlusions.
Prolonged ocular activity supporting extended dosing intervals of 4 to 8 weeks between injections.
Potential indirect reduction in retinal hemorrhages and exudates through vascular stabilization.
Minimal systemic pharmacologic effect due to localized intraocular administration.
Prevention of fibrosis and scarring secondary to neovascular processes in retinal diseases.
Binding to multiple angiogenic growth factors enabling broader anti-angiogenic effect.
Modulation of retinal microenvironment contributing to preservation of retinal structure.
Competitive binding to VEGF receptors reducing endothelial cell activation and migration.
Demonstrated dose-dependent pharmacologic efficacy in clinical trials involving diverse retinal pathologies.

Therapeutic Or Clinical Uses

Treatment of neovascular (wet) age-related macular degeneration (nAMD) to reduce vision loss.
Management of macular edema following retinal vein occlusion (RVO), including branch and central RVO.
Treatment of diabetic macular edema (DME) associated with diabetes mellitus.
Management of diabetic retinopathy (DR) to prevent progression and visual impairment.
Treatment of retinopathy of prematurity (ROP) in premature infants affecting retinal vascular development.
Reduction of fluid leakage and retinal swelling in conditions causing macular edema.
Improvement of visual acuity outcomes in patients with neovascular retinal disorders.
Potential off-label use in other ocular neovascular diseases under specialist discretion.
Preventive therapy to stabilize retinal anatomy in chronic retinal vascular pathologies.
Adjunctive treatment to other ophthalmic interventions for complex retinal diseases.
Used in patients contraindicated for laser therapy or in refractory retinal conditions.
Part of intravitreal injection protocols for long-term management of retinal neovascular diseases.
Therapy option for patients demonstrating suboptimal response to other anti-VEGF agents.
Treatment that may reduce the need for more frequent injections due to prolonged efficacy.
Approved for use in both unilateral and bilateral retinal vascular disorders as clinically indicated.

Side Or Adverse Effects

Redness and watering of the eyes following intravitreal injection.
Blurred vision and transient visual disturbances post-injection.
Swelling and discomfort of the eyelids and periocular area.
Mild to moderate ocular pain immediately after the injection procedure.
Development or progression of cataracts in treated eyes.
Increased intraocular pressure (elevation of eye fluid pressure) especially within 60 minutes post-injection.
Formation of vitreous floaters and possible vitreous detachment.
Superficial scratches or trauma to the corneal surface related to injection technique.
Conjunctival hemorrhage (bleeding in the front part of the eye) and retinal hemorrhage (bleeding at the back of the eye).
Serious ocular inflammation including endophthalmitis, a sight-threatening infection.
Retinal detachment occurring rarely as a complication of intravitreal injections.
Allergic or hypersensitivity reactions including ocular and systemic manifestations.
Potential transient increases in systemic blood pressure post-injection.
Symptoms such as eye pain, redness, swelling, or sudden vision changes requiring urgent evaluation.
Rare but serious arterial thromboembolic events including stroke or myocardial infarction.

Precautions

Administer only by qualified ophthalmic specialists experienced in intravitreal injections.
Monitor intraocular pressure following injection as transient elevations are common.
Evaluate eyes for infection or inflammation prior to each injection; avoid use if active infection is present.
Screen for hypersensitivity to aflibercept or excipients before initiation.
Use caution in patients with history of thromboembolic events or cardiovascular disease.
Pregnant women should avoid Eylea; effective contraception recommended during and up to 3 months after treatment.
Breastfeeding is contraindicated during treatment due to unknown excretion in human milk.
Observe patients for signs of endophthalmitis or intraocular inflammation post-injection.
Delay or withhold treatment if ocular adverse reactions or infections develop.
Patients should avoid driving or hazardous activities until visual acuity and eye comfort recover.
Inform patients of potential side effects and symptoms requiring immediate medical attention.
Careful handling and aseptic technique required to prevent ocular contamination and infection.
Adjust dosing intervals based on clinical response and tolerability.
Potential immunogenicity despite low incidence should be considered in long-term therapy.
Consider baseline ophthalmic examination and imaging prior to therapy initiation.

Warnings

Risk of increased intraocular pressure, possibly leading to optic nerve damage if untreated.
Serious risk of endophthalmitis following intravitreal injection that can cause vision loss.
Temporary visual disturbances common following injection; caution advised when driving or operating machinery.
Potential for serious ocular adverse reactions including retinal detachments and hemorrhages.
Systemic arterial thromboembolic events, though rare, have been reported post-injection.
Allergic reactions can be severe and require immediate discontinuation and treatment.
Avoid injection in presence of ocular or periocular infections, including conjunctivitis or keratitis.
Do not administer to patients with known hypersensitivity to aflibercept or formulation components.
Potential transient increase in blood pressure observed; monitor hypertensive patients accordingly.
Delay administration if signs of ocular inflammation are evident prior to scheduled dose.
Use with caution in patients with glaucoma or other conditions predisposing to elevated eye pressure.
Extensive patient counseling on injection procedure risks and warning signs is mandatory.
Follow strict sterile injection technique to minimize risk of contamination-related complications.
Monitor for systemic adverse events especially in patients with cardiovascular risk factors.
Benefit-risk balance must be evaluated continually during prolonged treatment courses.

Contraindication

Known hypersensitivity or allergy to aflibercept or any component of the formulation.
Active intraocular or periocular infection including bacterial, viral, or fungal infections.
Eyes with swollen, red, or inflamed tissue at the intended injection site.
Patients with ocular conditions that preclude safe intravitreal injection as determined by the clinician.
Pregnancy status requiring pregnancy testing due to potential fetal harm.
Concurrent or recent use of other intravitreal anti-angiogenic agents without appropriate washout period.
Patients unable or unwilling to comply with post-injection monitoring and follow-up requirements.
Use in combination with other biological therapies lacking safety data is contraindicated.
Known severe systemic hypersensitivity to monoclonal antibody therapies may warrant caution.
Conditions that significantly elevate risk for endophthalmitis if strict infection control is not possible.
Contraindications per local regulatory approvals or safety protocols that limit ophthalmic injection use.
Patients with history of thrombotic episodes without careful risk assessment may be excluded.
Severe ocular surface disease preventing safe intravitreal access or needle insertion.
Presence of dense vitreous hemorrhage or retinal detachment that require surgical intervention.
Any contraindication originating from patient-specific medical or ocular conditions as adjudicated by the ophthalmologist.

Drug Interactions

No significant drug interactions are established due to localized ocular administration of Eylea.
Systemic absorption is minimal, thus systemic drug interactions are unlikely but cannot be completely excluded.
Co-administration with other intravitreal anti-VEGF agents is generally avoided unless under specialist supervision.
Concurrent use of systemic anti-angiogenic agents or immunosuppressants has not been well studied; caution advised.
No known interactions with commonly used systemic medications such as antihypertensives or antidiabetics.
Potential additive effects on blood pressure should be considered if combined with antihypertensive drugs.
No significant interactions reported with anticoagulants or antiplatelet agents, but patient monitoring recommended.
Co-administration with ocular medications containing preservatives or irritants should be timed to reduce local irritation.
Interactions with herbal or over-the-counter supplements have not been documented but should be reported.
No formal pharmacokinetic interactions due to intravitreal route preventing systemic metabolic interactions.
No significant interference with diagnostic agents used in ophthalmic imaging reported.
Drug-drug interaction potential is low but vigilance for unexpected ocular or systemic effects is necessary.
Consider monitoring for increased intraocular pressure when coadministered with corticosteroids.
Advise patients to notify healthcare providers of Eylea therapy to avert potential drug interactions.
Lack of robust interaction data underscores the importance of individualized patient assessment.

Preparations Of The Drug

Eylea 2 mg/0.05 mL single-dose pre-filled syringe for ophthalmic intravitreal injection.
Eylea 2 mg/0.05 mL single-dose glass vial for ophthalmic intravitreal injection.
Both formulations contain 40 mg/mL aflibercept concentration with inactive ingredients including sodium phosphate, sodium chloride, polysorbate 20, and sucrose at pH 6.2.
Formulations are preservative-free to minimize risks of ocular toxicity and inflammation.
Supplied in sterile packages intended for single-patient use to maintain aseptic conditions.
Packaging includes necessary labeling for dosage, storage instructions, and administration guidelines.
Storage conditions generally recommend refrigeration at 2°C to 8°C and protection from light.
The drug is prepared under sterile environment to ensure safety and efficacy upon administration.
No additional compounding or dilution is typically required prior to intravitreal injection.
Syringes and vials are designed for ease of use by trained ophthalmologists or retinal specialists.
Disposal of unused material must follow biohazard and pharmaceutical waste protocols.
Preparation instructions emphasize avoiding contamination and maintaining cold chain during handling.
Manufactured by Regeneron Pharmaceuticals, ensuring quality control standards consistent with biologic drug products.
Patient information leaflets accompany products to educate regarding administration and safety.
Compatible injection devices must be utilized to ensure accurate dosing and minimal patient discomfort.